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Aim To investigate cardioprotective effect of taurine in dia-
betic rats.
Methods Male Sprague-Dawley rats were assigned ran-
domly into four groups of 15 rats: control group, con-
trol + taurine group, streptozotocin (STZ) group, and STZ + 
taurine group. Rats in STZ and STZ+ taurine groups were 
treated by a single injection of STZ (70 mg kg-1, intraperito-
neally) dissolved in 0.01 M citrate buffer (pH 4.5) for induc-
tion of diabetes, and rats in control and control + taurine 
groups were treated with the same volume citrate buffer. 
Taurine was orally administered to rats in control + taurine 
and STZ + taurine groups daily for 8 weeks. Rats were ex-
amined for diabetic cardiomyopathy by left ventricular (LV) 
hemodynamic analysis. Myocardial oxidative stress was as-
sessed by measuring the activity of superoxide dismutase 
(SOD) and the level of malondialdehyde (MDA). Myocardial 
protein kinase B (Akt/PKB) phosphorylation and heme oxy-
genase-1 (HO-1) protein levels were measured by Western 
blot in all rats at the end of the study.
Results In untreated diabetic rats, LV systolic pressure, rate 
of pressure rise, and rate of pressure fall were decreased, 
while LV end-diastolic pressure was increased, indicating 
reduced LV contractility and slowing of LV relaxation. The 
levels of Akt/PKB phosphorylation and SOD activity were 
decreased and HO-1 protein expression and MDA content 
increased. Taurine treatment significantly improved LV sys-
tolic and diastolic function, and there were persistent in-
creases in activities of Akt/PKB and SOD, and the level of 
HO-1 protein.
Conclusion Taurine treatment ameliorates myocardial 
function and heart oxidant status, while increasing myo-
cardial Akt/PKB phosphorylation, and HO-1 levels have 
beneficial effects on diabetic cardiomyopathy.
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Diabetes mellitus is a serious medical problem and has be-
come a significant health concern. Diabetic patients can de-
velop a specific cardiomyopathy called diabetic cardiomyo-
pathy (DCM) (1), which is an important contributing factor 
to heart failure in diabetic patients independent of athero-
sclerosis, hypertension, and other complications (2,3). Mech-
anisms responsible for DCM are still poorly understood, but 
direct toxic effect of hyperglycemia on cardiomyocytes and 
oxidative stress are hypothesized to play an important role 
in the pathogenesis of diabetes and its late complications 
(4). Hyperglycemia can lead to oxidative stress by a wide 
range of mechanisms, including glucose auto-oxidation, 
increased production of advanced glycosylation end prod-
ucts, and activation of the polyol and hexosamine pathways 
(5,6). Oxidative stress is thought to contribute to the initia-
tion and progression of cardiac dysfunction and remodeling 
of the extracellular matrix in the heart (7-9).
Heme oxygenase-1 (HO-1) is a ubiquitously expressed stress 
inducible enzyme that catabolizes heme into bilirubin, car-
bon monoxide (CO), and iron (10). The by-products of heme 
catabolism exert pleiotropic cytoprotective effects in the 
heart. Bilirubin is a powerful antioxidant (11), and CO exerts 
vasodilatory, anti-inflammatory, and anti-proliferative effects 
(12). Enhanced HO-1 expression enhances the concentration 
of p-AKT (13). Moreover, a large body of evidence has shown 
that activation of AMP-activated protein kinase (AMPK) and 
phosphorylated protein kinase B (p-Akt/PKB) increases the 
phosphorylation of a number of target molecules, resulting 
in increased glucose transport, fatty acid oxidation (14), and 
protection against oxidative stress (15-17).
Taurine (2-aminoethanesulphonic acid) is the major intrac-
ellular free β-amino acid, which is one of the most abundant 
free amino acids present in mammalian tissues and blood 
cells. It is involved in many important biological and physi-
ological functions, such as anti-oxidation, osmoregulation, 
membrane stabilization, and neurotransmission (18). Tau-
rine is a protective agent against oxidative stress-induced 
pathologies such as atherosclerosis (19), diabetic complica-
tions (18), and gastrointestinal (20) damage. It also has anti-
apoptotic properties and inhibits oxidative stress-induced 
apoptosis in several cells, such as hepatocytes (20).
The aim of this study was to examine whether taurine in-
creases HO-1 expression and ameliorates cardiac failure in 
type I diabetic cardiomyopathy. We examined left ventricu-
lar (LV) hemodynamic function, evaluated myocardial oxi-
dative stress, and myocardial levels of HO-1, connective 
tissue growth factor (CTGF), and p-AKT in the heart.
Methods
experimental animals and drug treatment
All animal procedures and experiments were conducted 
in accordance with the official recommendations of the 
Chinese Community Guidelines. Male Sprague-Dawley 
rats, weighting 180-220 g, were provided by the Exper-
imental Animal Center in Wannan Medical College and 
housed in a standard animal facility under controlled en-
vironmental conditions at room temperature, 22 ± 2°C 
and 12-hour light-dark cycle. Sixty rats were kept for 1 
week on balanced ration with water and food ad libitum 
for acclimatization. The animals were housed in stainless 
steel cages with sawdust bedding. Diabetes was induced 
by injecting a single dose of streptozotocin (STZ) (70 mg-
kg-1, intraperitoneally, dissolved in ice-cold sodium citrate 
buffer, 0.1M, pH 4.5), as previously described (21). Thirty 
age-matched control rats were treated with the same 
volume citrate buffer. Diabetes was confirmed 48 hours 
after STZ injection by measuring the glucose concentra-
tions of peripheral blood obtained from the tail vein (One 
Touch SureStep Meter, LifeScan, Milpitas, CA, USA). Dia-
betes was diagnosed by a sustained glucose concentra-
tion >15 mmol/L. Taurine (100 mg kg-1 per day) was ad-
ministered to the rats in the control + taurine and STZ + 
taurine group, and animals had free access to water after 
diabetes induction.
Cardiac function
After eight weeks of drug dosing, rats were anesthetized 
with sodium pentobarbital (50 mg/kg i.p.). The right ca-
rotid artery was cannulated with a Millar miniature cath-
eter and advanced into the aorta to record arterial pres-
sure. The aortic catheter was then advanced into the left 
ventricle for recording of left ventricular systolic pressure 
(LVSP), left ventricular developed pressure (LVDP), left ven-
tricular end diastolic pressure (LVEDP), maximum rate of 
rise/fall of left ventricle pressure (±dP/dtmax). All pressure 
data were recorded with MedLab data acquisition system 
(Nanjing MedEase Co., Nanjing, China) and fasting blood 
samples and hearts were collected and investigated on the 
same day.
Biochemical markers of myocardial injury in serum
Estimation of total cholesterol (TC), triacylglycerol (TG), low 
density lipoprotein (LDL), high density lipoproteins (HDL), 
creatine kinase (CK), and lactate dehydrogenase (LDH) in 
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the serum was done using appropriate kits on semi auto 
analyzer by well standardized methods (22).
determination of oxidative and anti-oxidative status
Heart homogenate (10%, w/v) was prepared with 0.1M PBS 
and centrifuged at 1200 g for 10 minutes. The supernatant 
was used to determine SOD activity and MDA level with 
commercially available kits (Nanjing Jiancheng Bioengi-
neering Institute).
Western blotting analysis
Heart samples (0.2 g) were lysed and homogenized in 2 
mL of lysis buffer (10 mM Tris-buffered saline, 1 mM EDTA, 
1 mM EGTA, 2 mM sodium orthovanadate, 0.2 mM PMSF, 2 
μg/mL leupeptin, 2 μg/mL aprotinin, and 1% Triton X-100) 
for 30 minutes on ice and cleared by centrifugation at 
13 000 g for 15 minutes at 4°C. Total protein concentration 
was determined in the supernatant using the Bradford as-
say (Bio-Rad Laboratories, Hercules, CA, USA). For each lane, 
equal amounts of protein were mixed with sodium dode-
cyl sulfate (SDS) sample buffer and boiled for 5 minutes. 
Samples were separated on a 10% sodium dodecyl sulfate-
polyacrylamide gel and transferred to 0.2-μm nitrocellu-
lose membrane. Nitrocellulose blots were blocked by incu-
bation in TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 
0.1% Tween 20) containing 5% non-fat milk for 1 hour at 
room temperature and incubated with a rabbit polyclonal 
anti-HO-1, AKT/PKB, phospho-AKT/PKB, CTGF, β-actin an-
tibody (1:500 dilution; Wuhan Boster Biotechnologies, 
Wuhan, China) overnight at 4°C. After 3 washing steps, a 
secondary anti-rabbit antibody (1:10 000 dilution; Sigma 
Chemical Co, St. Louis, MO, USA) was added and incubated 
for 1 hour. After rinsing with wash buffer for three times, 
the reaction was visualized by DAB (Bio Basic Inc. Markham 
Ontario, Canada). The relative amounts of the bands were 
quantified by densitometry using image software.
statistical analysis
Results are expressed as mean ± standard error of the 
mean of the values. Statistical significance for all variables 
was determined by analysis of variance (ANOVA) followed 
by a Tukey post hoc analysis by using SPSS, version 16.0 
(SPSS Inc., Chicago, IL, USA). P-values of <0.05 were consid-
ered significant.
ResuLts
Change in body weight and heart weight/body weight 
ratio (hW/BW)
After STZ administration, animals in STZ and STZ+ taurine 
groups showed similar levels of hyperglycemia. Diabetic 
rats treated with or without taurine had significantly low-
er body weight than controls (Table 1). However, STZ-dia-
betic animals had increased heart/body weight ratio. Tau-
rine treatment prevented body weight loss in diabetic rats 
compared with diabetic rats untreated with taurine. In ad-
dition, diabetic rats had an increased heart weight/body 
weight ratio, a marker for the development of diabetic car-
diomyopathy, and this ratio was significantly decreased by 
treatment with taurine (Table 1).
effects of taurine on cardiac function
Left ventricular hemodynamic parameters were measured 
in taurine-treated and un-treated control and diabetic 
groups of rats for assessment of ventricular performance. 
Un-treated diabetic rats showed a lower left LVSP, LVDP, and 
a higher LVEDP than control rats (Table 2). Also, untreated di-
abetic rats showed a decreased left ventricular ± dP/dtmax. 
Diabetic rats treated with taurine showed increased LVSP, 
LVDP, and reduced LVEDP, with a higher left ventricular ± dP/
dtmax. Untreated diabetic rats had significantly decreased 
heart rate (HR). Taurine treatment increased HR (Table 2).
taBLe 1. effect of taurine on blood glucose, body weight (BW), heart weight, and heart weight/body weight (hW/BW) ratio in 
control rats, control rats treated with taurine, streptozotocin (stZ) diabetic rats, and stZ diabetic rats treated with taurine (100 mg/
kg) (n = 8)*
Control Control + taurine stZ stZ+taurine
Blood glucose (mmol/L)   4.81 ± 0.65   4.73 ± 0.51  24.29 ± 3.09‡  22.35 ± 3.07
Body weight (BW) (g)† 394.6 ± 15.6 399.4 ± 14.1 169.6 ± 8.7‡ 275.6 ± 13.9§
Heart weight (HW) (g)†   1.24 ± 0.06   1.29 ± 0.07   1.05 ± 0.07‡   1.10 ± 0.06
HW/BW ratio (mg/g)   3.13 ± 0.19   3.23 ± 0.21   6.22 ± 0.56‡   3.99 ± 0.37§
*the results are expressed as mean ± standard error of the mean of the values. the number of animals per group was 8 for determination of blood 
glucose, BW, hW and hW/BW ratio levels.
†Body weight and heart weight were measured after 8 weeks.
‡P < 0.05 vs control group.
§P < 0.05 vs stZ group.
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effects of taurine on CK and Ldh
The levels of LDH and CK were significantly higher in un-
treated diabetic rats than in control rats. However, taurine 
treatment in diabetic rats markedly reduced the levels of 
LDH and CK compared with those in untreated diabetic 
rats (Figure 1).
effects of taurine on serum lipids profile
Taurine had a significant effect on lowering triglycerides, 
cholesterol, and LDL levels and increasing HDL levels in di-
abetic rats (Table 3). All these levels were completely nor-
malized after taurine treatment, which suggests that tau-
rine is far more effective in maintaining the lipid profile at 
the levels similar to those of controls in this animal model 
of diabetes.
antioxidant effects of taurine
The content of malondialdehyde equivalents in the heart, 
which reflects oxidant-induced lipid peroxidation reac-
tions, was significantly increased in diabetic animals (Fig-
ure 2). Taurine significantly improved the oxidant status, 
as evident from the reduction of malondialdehyde con-
centrations. SOD activity was significantly lowered in the 
hearts of untreated diabetic rats. Treatment with taurine 
significantly increased the activity of SOD.
Western blot analyses showed an accumulation of HO-1 
protein in diabetic rats compared with normal control and 
normal taurine rats (Figure 2). Taurine treatment led to a 
strong up-regulation of HO-1 protein compared with un-
treated rats (Figure 2).
expression of CtGF and p-akt/PKB following taurine 
treatment
Diabetes led to a reduced expression of p-Akt without af-
fecting the levels of Akt and increased expression of CTGF, 
while taurine partially restored STZ-induced loss of Akt 
phosphorylation and reduced the expression of CTGF (Fig-
ure 3A and 3B).
disCussion
This study showed that diabetes enhanced oxidative stress 
and impaired cardiac function and that treatment with 
taBLe 2. homodynamic parameters in control rats, control rats treated with taurine, streptozotocin (stZ) diabetic rats, and stZ 
diabetic rats treated with taurine (100 mg/kg) (n = 8)*†
Control Control + taurine stZ stZ+taurine
HR (bpm) †  420 ± 7  427 ± 9  307 ± 7‡  361 ± 9§
LVSP (mmHg) †  120.5 ± 1.4  124.8 ± 4.7   88.4 ± 2.2‡  104.5 ± 4.1§
LVEDP (mmHg) †    1.22 ± 0.2    1.15 ± 0.09    4.66 ± 0.86‡    3.48 ± 0.56§
LVDP (mmHg) †   84 ± 6.5   86 ± 5.5   52.9 ± 3.4‡   69 ± 6.2§
+dP/dtmax (mmHg/s) † 4285 ± 98 4254 ± 158 2418 ± 78‡ 3303 ± 81§
−dP/dtmax (mmHg/s) † 4180 ± 61 4015 ± 121 2295 ± 85‡ 3139 ± 98§
*abbreviations: hR – heart rate; LVsP – left ventricular systolic pressure; +dP/dt – rate of pressure rise; −dP/dt – rate of pressure fall; LVedP – left 
ventricular end-diastolic pressure; LVdP – left ventricular developed pressure.
†the results are expressed as mean ± standard error of the mean of the values. the number of animals per group was 8 for determination of hR, 
LVsP, +dP/dt, −dP/dt, LVedP, and LVdP levels. homodynamic parameters were measured after 8 weeks.
‡P < 0.05 vs control group.
§P < 0.05 vs stZ group.
taBLe 3. effects of taurine on serum lipid profile in control rats, control rats treated with taurine, streptozotocin (stZ) diabetic rats, 
and stZ diabetic rats treated with taurine (100mg/kg) (n = 8)*†
Control Control + taurine stZ stZ+taurine
TC (mmol/L) 1.51 ± 0.33 1.48 ± 0.30 5.04 ± 0.81* 3.05 ± 0.44†
TG (mmol/L) 0.75 ± 0.14 0.72 ± 0.18 2.37 ± 0.38* 1.34 ± 0.31†
LDL (mmol/L) 1.69 ± 0.30 1.66 ± 0.24 6.89 ± 0.92* 3.40 ± 0.57†
HDL (mmol/L) 1.31 ± 0.16 1.33 ± 0.14 0.37 ± 0.09* 0.62 ± 0.12†
*abbreviations: tC – total cholesterol; tG – triacylglycerol; LdL – low density lipoprotein; hdL – high density lipoproteins.
†the results are expressed as mean ± standard error of the mean of the values. the number of animals per group was 8 for determination of tC, tG, 
LdL, and hdL levels.
*P < 0.05 vs control group.
†P < 0.05 vs stZ group.
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taurine was beneficial to the hearts of diabetic rats as it 
restrained the progression of metabolic disorders of dia-
betes. STZ-diabetic rats showed elevated blood glucose 
levels. Also, there was a notable increase in the HW/BW ra-
tio, which signifies cardiac hypertrophy. Metabolically, the 
diabetic heart is characterized by diminished glucose utili-
zation and increased fatty acid oxidation, resulting in lipid 
accumulation in the myocardium (5,6). Taurine treatment 
showed a distinct positive effect on HW/BW ratio, indicat-
ing that taurine was able to prevent cardiac hypertrophy, 
which usually sets in as a result of diastolic dysfunction 
secondary to diabetes. Taurine also remarkably improved 
lipid profile and had a significant effect on lowering trig-
lyceride, cholesterol, and LDL levels and increasing HDL in 
diabetic rats. Untreated diabetic animals showed signifi-
cant decreases in LVSP, +dP/dt, and  − dP/ dt, and increas-
es in LVEDP. These hemodynamic alterations demonstrate 
abnormal left ventricular systolic and diastolic functions, 
which are the hallmark of diabetic cardiomyopathy. Tau-
rine treatment attenuated these hemodynamic changes.
Increases in levels of circulating cardiac damage markers, 
such as CK and LDH, represent a powerful and sensitive 
predictor of increased cardiac complications (23). In the 
present study, taurine-treated diabetic rats showed a sig-
nificant improvement in the levels of these markers. This in-
dicates that taurine prevents cardiac damage and has ben-
eficial properties. The decrease in the markers in diabetic 
rats treated with taurine suggests that taurine reduced the 
risk of metabolic disorders associated with diabetes.
Increased oxidative stress and altered antioxidant pool 
have been found in both clinical and experimental type 
1 diabetes (24). This was in conjunction with depletion of 
superoxide scavenger SOD and increase in lipid peroxida-
tion product MDA. Taurine is often referred to as a semi-
essential amino acid because it is not used in protein syn-
thesis. It amounts to a large proportion of the total free 
amino acids in the heart, kidney, and plasma (25) and is 
vital for normal development. A recent study indicated 
that taurine was able to ameliorate diabetic cardiomyo-
pathy by down-regulating AT2 receptors (26), and dietary 
supplementation of taurine attenuated diabetes-induced 
changes in cardiac contractile function and ultrastructure 
(27). It was also reported to have beneficial effects in vari-
ous physiological and pathological conditions by mainly 
diminishing production of reactive oxygen species (ROS) 
(18). The present study showed that STZ-induced diabetic 
condition resulted in an increase in the lipid peroxidation, 
which is the direct indicator of systemic oxidative stress. 
Taurine treatment in diabetic rats reduced the formation 
of lipid peroxides and also restored the levels of SOD in the 
diabetic hearts. HO-1, the inducible isoform of the HO sys-
tem, is a rate-limiting enzyme, which converts heme into 
equimolar amounts of iron, carbon monoxide, and biliver-
din. HO-1 is thought to have antioxidant and cytoprotec-
tive roles (28). Taurine treatment significantly increased 
the level myocardial HO-1 in the STZ-diabetic rats. 
FiGuRe 1. the levels of creatine kinase and lactate dehydroge-
nase in serum from control and streptozotocin (stZ) diabetic 
rats treated with or without taurine (100 mg/kg). (A) creatine 
kinase (CK); (B) lactate dehydrogenase (Ldh). Cont – control 
rats; cont + taur – control rats with taurine; stZ – diabetic rats; 
stZ+taur – diabetic rats with taurine. the results are expressed 
as mean ± standard error of the mean. the number of animals 
per group was 8 for determination of CK and Ldh activities. 
*P < 0.05 vs control (cont) group, † P < 0.05 vs stZ group.
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This beneficial effect of taurine could be directly attribut-
able to its antioxidative nature, which is in agreement with 
previous findings (29). The elevated level of serum lipids 
in DM causes the risk of coronary heart disease (30), while 
in some studies, HDL was found to be cardioprotective 
(31). Serum lipids like TC, TG, and LDL were significantly 
decreased and HDL was significantly increased in diabetic 
rats treated with taurine. Taurine is known to have antioxi-
dant properties (18,20) and this may reduce the suscep-
tibility of lipids to oxidation and stabilize the membrane 
lipids, thereby reducing oxidative stress.
Akt is an important downstream effector of insulin signal-
ing, critical for regulation of cardiac growth and survival 
(32), while the PI3K/Akt cascade is an important surviv-
al pathway in the heart. Akt overexpression leads to in-
creased survival and improved myocardial function (33). 
Cytoprotective effect of HO-1 is mediated via activation 
of the PI3K/Akt pathway (34). Insulin has been reported 
to increase HO-1 mRNA and protein expression in a time- 
and dose-dependent manner with maximum effects at 
3 and 12 hours, respectively. The mechanisms by which 
insulin promotes HO-1 levels were further analyzed and 
showed that insulin induced HO-1 mRNA expression 
through activation of PI3-kinase/Akt pathway (35). HO-1 
may be induced by inflammation and/or oxidative stress, 
which generates transcription factors activated by p-AKT 
and then increases the level of HO-1 protein (36). Recent 
FiGuRe 2. the levels of malondialdehyde and superoxide dismutase in cardiomyocyte from control and streptozotocin (stZ) diabetic 
rats treated with or without taurine (100 mg/kg). (A) malondialdehyde (Mda); (B) superoxide dismutase (sod); (C) Representative 
gel blots of heme oxygenase-1 (ho-1) and β-actin (loading control) using specific antibodies; (D) ho-1 expression. Cont – control 
rats. Cont + taur – control rats with taurine. stZ – diabetic rats. stZ+taur – diabetic rats with taurine. the results are expressed as 
mean ± standard error of the mean. the number of animals per group was 8 for determination of Mda and ho-1 levels and sod 
activity. *P < 0.05 vs control (cont) group, †P < 0.05 vs stZ group.
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evidence suggests that these two enzyme systems inter-
act both at the posttranscriptional and posttranslational 
levels (37). CTGF has been demonstrated to play an im-
portant role in fibrotic response through a transforming 
growth factor-beta 1 (TGF-β1) -dependent or indepen-
dent pathway (38). CTGF acts as a cofactor with TGF-β to 
induce fibroblasts to become myofibroblasts that deposit 
collagen, ultimately resulting in organ scarring and dys-
function, and in the most severe forms, organ failure and 
death. Indeed, CTGF levels in tissue, blood, or vitreal fluid 
have been shown to correlate with the degree and sever-
ity of fibrosis in many diseases (39). Other studies showed 
that CTGF also exhibited prohypertrophic properties on 
cardiomyocytes (40). Furthermore, CTGF has been pro-
posed as a heart failure biomarker (41) and found to be 
induced by stress in cultured cardiomyocytes (42). Many 
studies showed that PKC up-regulated CTGF by inhibiting 
the PI3K/Akt pathway in the diabetic heart (43). Our study 
showed that taurine could increase p-Akt expression and 
antioxidant levels and reduce CTGF expression. This sug-
gests that the protective effect of taurine against DCM 
takes place at least in part via increasing antioxidant levels 
and reducing fibrosis.
In summary, the present findings show that treatment with 
taurine may attenuate the progressive cardiac dysfunction 
and myocardial oxidative stress in a murine model of dia-
betic cardiomyopathy. The beneficial effect of taurine is a 
result of its inhibition of myocardial oxidative stress pro-
cesses through its potential autoregenerative antioxidant 
properties. Evidence indicates that any treatment that is 
able to modulate oxidative stress and enhance antioxidant 
would help to delay the onset of DCM in diabetes mellitus. 
Thus, we suggest further exploration of the role of antioxi-
dant therapy given immediately after the diagnosis of type 
I diabetes mellitus to reduce the risk of future cardiovascu-
lar complications.
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